



## **NEWS RELEASE**

### **MDxHealth Amends Existing Methylation Biomarker Agreement with Veridex, LLC**

#### **Partnering of Cancer Screening Applications Supports MDxHealth's New Strategy**

**DURHAM, NC, and LIEGE, BELGIUM** – December 15, 2010 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced it has renewed its existing agreement with Veridex for the use of certain of its proprietary DNA methylation products in blood testing for colorectal cancer and prostate cancer screening. The transaction demonstrates MDxHealth's ability to deliver on its recently announced new strategy of developing and commercializing its DNA methylation products itself through a CLIA laboratory in the U.S. while out-licensing its methylation technology for cancer screening applications at an accelerated pace and as broadly as possible.

Under the revised agreement, the Company grants Veridex non-exclusive rights for worldwide laboratory service testing to MDxHealth's DNA methylation biomarkers for use in blood-based detection of colorectal cancer, as well as tissue and urine-based detection of prostate cancer. In return, MDxHealth will receive milestone payments and royalties on net sales. Financial terms were not disclosed.

The new agreement replaces a broader agreement under which Veridex had exclusive rights to certain MDxHealth DNA methylation biomarkers for all resulting new products.

"This agreement demonstrates how quickly MDxHealth has been able to deliver on our new strategy. It greatly simplifies our contractual obligations and at the same time it could potentially provide revenues from future royalty streams from prostate and colorectal cancer screening applications developed by Veridex," said Dr. Jan Groen, Chief Executive Officer of MDxHealth.

#### **About MDxHealth**

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing and companion diagnostics for personalized medicine. The company's numerous cancer tests are based on proprietary gene methylation technology and are designed to assist physicians in the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research centers such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders.

#### **MDxHealth to present at Biotech Showcase in San Francisco on January 10, 2011**

MDxHealth will present at the Biotech Showcase Conference in San Francisco, on Monday, Jan. 10, 2011. Dr. Jan Groen, chief executive officer, will make a formal presentation on the company at 2 p.m. Pacific time. The Biotech Showcase runs parallel to the 28th Annual J.P. Morgan Healthcare Conference, and takes place at Parc 55 Wyndham San Francisco - Union Square.

**For more information:**

Dr. Jan Groen, CEO  
MDxHealth  
+32 4.364.20.70  
[IR@MDxHealth.com](mailto:IR@MDxHealth.com)

Hans Herklots  
Capricorn One  
+41 79 598 7149  
[capricorn1@bluewin.ch](mailto:capricorn1@bluewin.ch)

*This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.*